HOME >> BIOLOGY >> NEWS
Elusive cancer killer's deep-sea hideout discovered after a nearly 20-year hunt

les and took the team throughout the island chain almost as far south as the Turks and Caicos Islands. For more information about this expedition as well as background articles on the team's research, please visit HARBOR BRANCH's online expedition site at: http://www.at-sea.org

HARBOR BRANCH has already patented nearly a hundred potential pharmaceuticals from the tens of thousands of the organisms the Biomedical Marine Research group has collected since the '80s at sites around the globe. Several of these are in various stages of development as potential commercial drugs. Discodermolide, a compound produced by a deepwater sponge found in the Bahamas, is currently in the first phase of human trials as a cancer treatment.


'"/>

Contact: Mark Schrope
schrope@hboi.edu
772-216-0390
Harbor Branch Oceanographic Institution
27-Oct-2003


Page: 1 2 3

Related biology news :

1. Elusive but ubiquitous microbe fingered as gum disease culprit in Stanford study
2. Studies At Cedars-Sinai Confirm Identity Of An Elusive Receptor In Human Cells -- A Breakthrough In Understanding, Fighting Septic Shock
3. Wisconsin Scientists Culture Elusive Embryonic Stem Cells
4. Leader in cancer treatment and prevention research honored
5. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
6. Chemical derived from vitamin-E shows early promise as cancer drug
7. New molecular link key to cellular proteins involved in cancer progression, other diseases
8. Phase II trials of second-generation antisense cancer drug planned following successful early study
9. Trial shows which brain cancer patients benefit from temozolomide
10. Genetic differences might help distinguish thyroid cancers
11. Evidence builds for potential new cancer drug target

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions LLC ... services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ... patients with severe COVID-19. This is the first study of an XPO1 inhibitor ...
(Date:6/23/2020)... ... June 22, 2020 , ... The field of quantitation of large molecules ... have dominated this area. However, the use of mass spectrometry in this field has ... the question “How do you choose which approach to use (LBA or MS)?” ...
(Date:6/19/2020)... ... June 16, 2020 , ... The director of stem cell ... if the stem cell medicine and pharmaceutical industries have easier access to stem cell ... starting July 5 of this year, Independence Day weekend in the U.S., Asymmetrex is ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 11, 2020 , ... The FSHD ... Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration ... is a consortium of academic research centers in the United States and Europe ...
(Date:8/7/2020)... , ... August 06, 2020 , ... ... vaccine industries, announces it has closed on the purchase of greenfield for a ... Conroe, TX and includes over 21 acres in the initial acquisition, with an ...
(Date:7/31/2020)... ... 29, 2020 , ... R3 Stem Cell International is now offering patients the ... stem cells total, patients may choose which extremities they would like treated. , Several ... Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from a lab ...
(Date:7/31/2020)... ... July 29, 2020 , ... Anomet Products ... three different materials for use with CRM, neurostimulation, vascular, and related devices. , ... meet specific design requirements, performance, and cost criteria; especially where solid wire is ...
Breaking Biology Technology:
Cached News: